BioWorld

Oct. 14, 2010

View Archived Issues

New Inhibitor Keeps Hepatitis C from Getting Itself Together

Read More

Fate Strikes Technology Deal to Expand R&D IPSC Tools

Read More

Corrections & Clarifications

Read More

FDA Calls for Bone Fracture Warnings on Bisphosphonates

Read More

Clinic Roundup

Read More

Stock Movers

Read More

Other News To Note

Read More

Alkermes Aims Higher with New Indication for Vivitrol

With its FDA approval this week, Vivitrol becomes the first non-addictive, non-narcotic, once-monthly treatment for opioid dependence, serving a potential market of 1.3 million addicts in the U.S. (BioWorld Today) Read More

Regeneron Raises $175.1M in Upsized Public Offering

Read More